{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017454","form_type":"8-K","ticker":"STOK","cik":"0001623526","company_name":"Stoke Therapeutics, Inc.","filed_at":"2023-05-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.712916+00:00","generated_at":"2026-06-15T22:09:49.639708+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Stoke Therapeutics Q1 2023 net loss $0.53/sh; cash $254.2M; mid-2023 STK-001 data expected","bullets":["Net loss per share $0.53, revenue $5.2M from collaboration (up from $3.0M YoY).","Cash, equivalents and securities $254.2M, expected to fund operations to end of 2025.","On track to report Phase 1/2a STK-001 data mid-2023: safety & seizure frequency for up to 16 patients on 45mg.","UK MHRA authorized CTA for STK-002 Phase 1/2 study in ADOA; start expected early 2024.","Company plans to initiate a Phase 3 program in 2024, pending additional Phase 1/2a data."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017454","json":"https://secwatch.observer/filing/0000950170-23-017454.json","markdown":"https://secwatch.observer/filing/0000950170-23-017454.md","text":"https://secwatch.observer/filing/0000950170-23-017454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1623526/000095017023017454/0000950170-23-017454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1623526/000095017023017454/stok-20230504.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T22:09:49.639708+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fd7a4380fe856712ddc484826a13ad17d922ea00","claim":"Stoke Therapeutics, Inc. reported three months ended March 31, 2023 results: net income -$22.5 million, EPS -$0.53.","evidence_excerpt":"Net loss for the three months ended March 31, 2023 was $22.5 million, or $0.53 per share, compared to $24.6 million, or $0.66 per share, for the same period in 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1623526/000095017023017454/0000950170-23-017454-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Net income","value":"-$22.5 million"},{"label":"EPS","value":"-$0.53"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}